HealthEquity, Inc.

Valuation Analysis

About the Company

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. It offers health savings accounts (HAS); investment platform; online-only automated investment advisory services through Advisor, a Web-based tool. The company also provides flexible spending accounts (FSA) for health and dependent care; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. In addition, the company offers HSA and FSA members with access to certain healthcare products, programs, and services through its marketplace. It serves clients through a direct sales force; and brokers and advisors, a network of health plans, benefits administrators, benefits b

HealthEquity, Inc. Stock at a Glance

HealthEquity, Inc. (HQY) is currently trading at $88.34 with a market capitalization of $7.4B. The trailing P/E ratio stands at 33.09x, with a forward P/E of 16.09x. The 52-week range spans from $72.76 to $106.60; the current price is 17.1% below the yearly high. Year-over-year revenue growth stands at +7.2%. The net profit margin stands at 17.25%.

💰 Dividend

HealthEquity, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

16 analysts rate HealthEquity, Inc. (HQY) on consensus: Buy. The average price target is $115.56, implying +30.82% from the current price. Analyst price targets range from $88.00 to $135.00.

HealthEquity, Inc.: The Investment Case in Detail

HealthEquity, Inc. (HQY) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 34.4% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 70.68%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 17.25%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

The Bear Case

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The PEG ratio at 1.27 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

What to Watch Next

• The forward P/E of 16.09x is meaningfully below the trailing 33.09x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 30.82% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (6.54%).

Trading Data

Related Stocks in the Same Sector

Where can I buy HealthEquity, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.